Examples of 'ustekinumab' in a sentence
Meaning of "ustekinumab"
Ustekinumab (noun) - Ustekinumab is a prescription medication used to treat conditions such as psoriasis and psoriatic arthritis. It belongs to a class of drugs known as biologics and works by blocking certain proteins in the body that contribute to inflammation and autoimmune reactions
Show more definitions
- A human monoclonal antibody directed against interleukin 12 and interleukin 23, in clinical trials for multiple sclerosis, psoriasis, and psoriatic arthritis.
How to use "ustekinumab" in a sentence
Basic
Advanced
ustekinumab
Stelara contains the active substance ustekinumab.
It is not known if ustekinumab is absorbed systemically after ingestion.
The exact metabolic pathway for ustekinumab is unknown.
Ustekinumab is used to treat psoriasis.
It is unknown whether ustekinumab is excreted in human breast milk.
Similar results were seen with each dose of ustekinumab.
Animal studies have shown excretion of ustekinumab at low levels in breast milk.
Appropriate techniques for administration of ustekinumab.
Immunosuppressants like ustekinumab have the potential to increase the risk of malignancy.
Patients were randomized to receive subcutaneously administered ustekinumab or etanercept.
It has also been shown that ustekinumab is effective in the treatment of psoriatic arthritis.
The active substance is ustekinumab.
Antibodies to ustekinumab may develop during ustekinumab treatment and most are neutralising.
There are no adequate data from the use of ustekinumab in pregnant women.
Steady state ustekinumab concentration was achieved by the start of the second maintenance dose.
See also
Concomitant use of immunomodulators did not have a significant impact on ustekinumab disposition.
Superiority of ixekizumab versus ustekinumab was also demonstrated in the subgroups stratified by weight.
In patients treated with secukinumab compared to patients treated with ustekinumab.
No specific studies have been conducted with intravenous ustekinumab in elderly or paediatric patients.
Stelara is a solution for injection that contains the active substance ustekinumab.
Ustekinumab may have the potential to increase the risk of infections and reactivate latent infections.
No new safety findings were observed in patients who switched from ustekinumab to guselkumab.
Ustekinumab has been approved in Canada for the treatment of psoriasis for several years.
The majority of patients who were positive for antibodies to ustekinumab had neutralizing antibodies.
Ustekinumab is an immunosuppressant, and it may increase the risk for malignancy.
We need more studies to demonstrate the safety of new biological drugs different from ustekinumab.
Serum concentration-time profiles of ustekinumab were generally predictable after single or multiple subcutaneous dose administrations.
Following response to IV ustekinumab.
Ustekinumab and briakinumab for the treatment of active Crohn 's disease.
Recommended dose of Ustekinumab.
Cancer - Ustekinumab has very rarely been associated with developing cancer.
Weeks and were allowed to dose adjust to receive ustekinumab every 8 weeks.
Infusion dose of ustekinumab using the weight-based dosage regimen specified in Table 1.
Project, Harmonized biomarkers to measure response to ustekinumab in type 1 diabetes.
The pharmacokinetics of ustekinumab were generally comparable between Asian and non-Asian patients with psoriasis.
What STELARA contains • The active substance is ustekinumab.
The CL / F of ustekinumab was not impacted by gender.
PASI-Response Rates from comparative study ixekizumab versus ustekinumab.
The CI / F of ustekinumab was not impacted by gender.
At week 12, placebo treated patients crossed over to receive ustekinumab.
Each vial contains 90 mg ustekinumab in 1 ml of solution for injection.
In patients with psoriasis, exfoliative dermatitis has been reported following ustekinumab treatment see section 4.8.
Mg ustekinumab every 8 weeks.
STELARA 45 mg solution for injection in pre-filled syringe ustekinumab.
The effect of ustekinumab on human fertility has not been evaluated see section 5.3.
Cuchacovich reported the same comparison in 2011 and reassured the findings of Griffiths with ustekinumab.
And 3 . Studies with ustekinumab in Psa are underway.
STELARA 45 mg solution for injection ustekinumab SC.
Each vial contains 130 mg ustekinumab in 26 mL of concentrate for solution for infusion.
Biologics for immunosuppression include Adalimumab, Certolizumab, etanercept, Golimumab, Infliximab, and ustekinumab.
